Clinical Trial

Precision Medicine for L/GCMN and Melanoma 2

Study acronym: Precis-mel 2
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-18.
Status change: Not Yet Recruiting → Recruiting 2025-02-25
Trial Details
NCT Number NCT06605443
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Collaborators: Hospital Clinic of Barcelona
Conditions Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus
Enrollment 100 participants
Start Date 2025-01-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-27